Taysha Gene Therapies, Inc. (TSHA)

USD 1.83

(-9.85%)

Market Cap (In USD)

375.04 Million

Revenue (In USD)

15.45 Million

Net Income (In USD)

-111.56 Million

Avg. Volume

1.93 Million

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.19-4.32
PE
-
EPS
-
Beta Value
0.414
ISIN
US8776191061
CUSIP
877619106
CIK
1806310
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Sean P. Nolan
Employee Count
-
Website
https://www.tayshagtx.com
Ipo Date
2020-09-24
Details
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.